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system (OMS), thus allowing individual patient dose records 
to be monitored and radiotherapy imaging dose reference 
levels (DRLs) to be developed. 
 
Material and Methods: DICOM query/retrieve is used to index 
and fetch CT dose report objects known to the PACS. 
Protocol information, patient details, CTDI and DLP are 
extracted. A script runs against the OMS and extracts CBCT 
activity information, including exposure settings and scan 
length. All information is converted into a standard format 
and stored in a data warehouse structured to make data 
exploration straightforward using readily available reporting 
and data mining tools. Data can be plotted and tabulated as 
a function of scanner, linac, operator, day of week, etc. 
Authorised operators can drill down to the patient, study and 
series level to understand the pre-treatment and linac 
imaging performed on individual patients and review the 
overall imaging dose record. Data can also be presented 
anonymised or pseudonymised for research, development and 
audit purposes. 
 
Results: Table 1 shows data volumes and extract timings for 
a large centre (8 linacs with CBCT). The processing burden to 
update the data warehouse on a nightly basis is negligible. 
 
Radiotherapy pre-treatment exposures were consistent with 
the equivalent diagnostic investigations and both were in line 
with local and national DRLs. There was clear evidence that 
when more advanced and automated linac imaging 
equipment is available more CBCTs are acquired (linacs VT1 
and VT3 in Figure 1). Optimisation strategies can be studied 
by reviewing dose information alongside image quality and 
clinical decision making (see Figure 2, where dose differs 
between linacs and was deliberately increased when imaging 
a large patient). 
 
 
It was found that ARIA does not always correctly record CBCT 
exposure information, although if linac imaging is protocol 
driven there is a unique relationship between recorded values 
and protocol selected. Also, body site information may be 
coded differently between CT scanners. Data warehouse 
mapping tables were employed to identify the actual CBCT 
protocols utilised and standardise site descriptions. 
 
Conclusion: An automated data warehouse empowers 
professionals who are not IT experts to ask clinically relevant 
questions of a rich data source of imaging performance and 
dose information. 
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Purpose or Objective: Radiosurgery (SRS) and stereotactic 
radiotherapy (SRT) are known to deliver very high doses per 
fraction. The corresponding peripheral dose can be a limiting 
parameter which potentially generates late toxicities. The 
purpose of this study was to evaluate peripheral dose 
delivered to healthy tissues such as thyroid and gonads for 
brain SRS/SRT treatments performed with a Cyberknife® 
M6TM system. 
 
Material and Methods: Measurements were performed on a 
Cyberknife® M6TM (Accuray) equipped with fixed and IrisTM 
collimator systems. Doses were measured with GR200A 
(LiF:Mg, Cu, P) thermoluminescent dosimeters (TLD). Each 
TLD was individually calibrated in a 6 MV beam. TLD readings 
were performed with a PCL3 automatic reader (FIMEL). 
Firstly, in-vitro measurements were carried out in an 
anthropomorphic phantom (CIRS ATOM 701-c) for different 
typical brain treatment plans using different beam apertures 
(5 mm to 60 mm). Peripheral doses were measured at 24 
points distributed from thyroid to gonads on the median line 
of the phantom (between 15 cm and 82.5 cm from the PTV 
center). Secondly, in-vivo measurements were performed on 
30 patients, in 4 points representative of thyroid, breast, 
umbilicus and gonads. The number of monitor units (MU) used 
for treatment plans ranged from 5499 MU to 28900 MU with a 
mean value of 13737 MU, delivered in 1 to 3 fractions. 
Results were compared with peripheral dose published for 
previous Cyberknife® versions. Treatment plans were 
calculated with Multiplan v5.1.2 (Accuray). Peripheral dose 
were reported in cGy as percentage of the number of 
delivered Monitor Units (% of MU). 
 
Results: Peripheral dose varied according to collimator size: 
0.043 % of MU at 15 cm for a 5 mm collimator aperture and 
0.235 % of MU at 15 cm for a 60 mm collimator aperture. For 
an intermediate collimator aperture (20 mm), peripheral 
doses were between 0.062 % of MU at 15 cm and 0.036 % of 
MU at 40 cm for fixed collimator system and between 0.040 % 
of MU at 15 cm and 0.029 % of MU at 40 cm for IrisTM 
collimator system. Table 1 compares our in-vivo 
measurements with peripheral dose published in the 
literature on several Cyberknife® models [1,2]. 
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Conclusion: Peripheral dose for the Cyberknife® M6TM 
version is lower than previous Cyberknife® versions. 
Nevertheless, for a brain treatment the dose can reach 10 
cGy in the thyroid and can exceed 7 cGy in gonads; it should 
be evaluated for every localization. Peripheral dose will 
depend on number of monitor units, beam aperture size and 
collimator system. These parameters should be optimized 
during treatment planning to limit peripheral dose as lower 
as possible. 
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Purpose or Objective: Several dosimetric methods were 
proposed to overcome limitations of the standard dose index 
used for CT dosimetry (CTDI100) with cone beam computed 
tomography (CBCT). Two of these methods were proposed by 
IEC and AAPM. The aim of this project was to investigate the 
correlation between organ doses (ODs) resulting from head, 
thorax, and pelvic CBCT scans and the IEC and AAPM 
methods. 
 
Material and Methods: The IEC method (CTDIIEC) is based on 
measuring CTDI100 using a reference beam and the 
application of a correction factor based on free-in-air CTDI 
measurements, while the AAPM method f(0) is based on 
measuring cumulative dose using a small ionization chamber 
at the middle of an infinitely long phantom ≥450 mm. 
CTDIIEC was evaluated within CTDI head and body phantoms, 
whereas f(0) was assessed within 450 mm long CTDI 
phantoms. CTDIIEC and f(0) were measured at the centre and 
periphery of the phantoms using head, thorax, and pelvic 
scanning protocols used in the clinic. ODs were evaluated in 
terms of absorbed dose to organs and tissues using Monte 
Carlo simulations on the ICRP-110 adult male and female 
reference computational phantoms. BEAMnrc and DOSXYZnrc 
user codes were utilized to simulate On-Board Imager (OBI) 
system mounted on a TrueBeam linac and to assess ODs using 
the same scanning protocols used for CTDIIEC and f(0). The 
correlation was studied as the difference between weighed 
values (2/3 periphery:1/3 centre) of CTDIIEC,w and f(0)w and 
ODs. The correlation was investigated for organs, which have 
higher weights of effective dose.  
 
Results: For head scan, CTDIIEC,w were smaller than doses to 
bone marrow, brain, and salivary gland by 4-55% for male and 
by 16-84% for female. f(0)w was also smaller than doses to 
bone marrow and salivary gland by 7-26% and 49-50% for male 
and female, respectively, but was larger than brain dose by 
15% and 5%, respectively. For thorax scan, doses to bone 
marrow, lung, breast, and oesophagus were underestimated 
by CTDIIEC,w and f(0)w by 61-100% and 35-58% for male and 
by 108-161% and 64-106% for female, respectively. However, 
CTDIIEC,w and f(0)w overestimated doses to stomach and 
thyroid by 10-34% and 29-45% for male and by 13-28% and 31-
43% for female, respectively. For pelvic scan, CTDIIEC,w and 
f(0)w were smaller than doses to bone marrow and urinary 
bladder by 91-173% and 51-116%, respectively, but were 
larger than colon and gonads doses by 30-78% and 44-82%, 
respectively, for male. For female, however, doses to all the 
organs were underestimated by CTDIIEC,w and f(0)w by 76-
204% and 40-141%, respectively. 
 
Conclusion: The correlations between CTDIIEC,w and f(0)w 
and ODs were comparable to the majority of organs. In 
general, however, f(0)w gave a better estimation for ODs 
compared to CTDIIEC,w for the scanning protocols studied. 
 
EP-1624  
Influence of organ motion on radiation-induced secondary 
cancer for VMAT and IMPT of prostate cancer 
C. Stokkevåg
1Haukeland University Hospital, Department of Oncology and 
Medical Physics, Bergen, Norway 
1, G. Engeseth1, L. Hysing1, K. Ytre-Hauge2, L. 
Muren3 
2University of Bergen, Department of Physics and 
Technology, Bergen, Norway 
3Aarhus University Hospital, Department of Medical Physics, 
Aarhus, Denmark 
 
Purpose or Objective: An elevated risk of radiation-induced 
secondary cancer (SC) in directly irradiated tissues such as 
the bladder and rectum has been observed in prostate cancer 
patients following radiotherapy (RT). There are considerable 
fluctuations in SC risk due to inter-patient anatomy 
variations, indicating the relevance of also including the 
effects of internal organ motion for individual patients. Both 
the bladder and rectum are highly mobile structures and the 
aim of this study was therefore to investigate the influence 
of organ motion on SC risk. 
 
Material and Methods: Simultaneously integrated boost 
treatment plans were generated on the planning CT (pCT) 
scans of eight prostate patients, using volumetric modulated 
arc therapy (VMAT) and intensity-modulated proton therapy 
(IMPT). Both VMAT and IMPT plans were prescribed to deliver 
67.5 Gy to the prostate and 60 Gy to the seminal vesicles 
over 25 fractions, using fiducial marker based image 
guidance. Each patient had 8-9 repeat CT (rCT) scans 
throughout the course of treatment on which the bladder and 
rectum were re-contoured and the originally planned dose 
distribution re-calculated. Relative risk (RR) of radiation-
induced cancer were calculated from the planned and re-
calculated dose distributions by using the organ equivalent 
dose concept adapted to dose-response models reflecting 
varying degrees of cell sterilisation: a linear model, a linear-
plateau model and a bell-shaped competition model. 
 
Results: Using the competition model, the RRs of bladder 
cancer based on the pCTs ranged from 0.4 to 3.4, while a 
considerably wider range was found when including all rCTs 
(from 0.2 to 6.7). Similar trends were seen for the RR for 
rectal cancer with the competition model and also for both 
bladder and rectal cancer using the linear model (Fig 1). 
Overall, the ranges were narrower with the linear model 
compared to competition model (Fig 1). For 4/8 patients for 
the bladder and 1/8 patients for the rectum, the estimated 
risks according to the competition model were consistently 
lower for IMPT compared to VMAT. Using the linear model the 
corresponding fractions were 6/8 and 7/8 patients. The 
remaining patients had rCTs with variations in RR, favouring 
either VMAT or IMPT, except one of the patients with all rCTs 
in favour of VMAT for rectal cancer using the competition 
model. In particular for the competition model, the RRs 
according to the pCT were often found at the upper or lower 
side of the RR across rCTs and two cases for bladder cancer 
and three cases for rectal cancer had RR <1 when addressed 
with the pCT but a median RR>1 across the rCT. 
 
